These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9254309)

  • 1. [Worry about the IGM is not justified].
    Mandahl H
    Lakartidningen; 1997 Jul; 94(28-29):2529. PubMed ID: 9254309
    [No Abstract]   [Full Text] [Related]  

  • 2. [How to improve drug information!].
    Järhult B
    Lakartidningen; 1998 Jul; 95(30-31):3278-9. PubMed ID: 9715057
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug control within the EEC II: good possibilities for Sweden].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(4):178-9. PubMed ID: 1734147
    [No Abstract]   [Full Text] [Related]  

  • 4. [Scrutiny of drug marketing by drug industry].
    Perman E
    Lakartidningen; 2003 Apr; 100(16):1444-5. PubMed ID: 12756713
    [No Abstract]   [Full Text] [Related]  

  • 5. [The inspection of information: "Hidden" comparison, words of evaluation often cause notifications].
    Lakartidningen; 1996 Aug; 93(32-33):2763-5. PubMed ID: 8765603
    [No Abstract]   [Full Text] [Related]  

  • 6. [We don't receive sufficient information about calcium blockers and other drugs].
    Lindeberg S
    Lakartidningen; 1995 Oct; 92(43):3977. PubMed ID: 7475518
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality control of drug information transfer.
    Ruskin A
    Drug Inf J; 1975; 9(2-3):89-90. PubMed ID: 10236984
    [No Abstract]   [Full Text] [Related]  

  • 8. [Physicians report verbal drug information. Cases scrutinized by the IGM].
    Perman E
    Lakartidningen; 2004 Aug; 101(35):2648, 2650. PubMed ID: 15458219
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prohibited marketing and shift in meaning of indications--a case for the IGM].
    Perman E
    Lakartidningen; 2003 Jul; 100(28-29):2378-9. PubMed ID: 12899031
    [No Abstract]   [Full Text] [Related]  

  • 10. Is drug advertising informing the consumer?
    Hanlon PM
    Behav Healthc Tomorrow; 2002 Feb; 11(1):SR35-7. PubMed ID: 11837141
    [No Abstract]   [Full Text] [Related]  

  • 11. [Offer for better drug information].
    Højgaard L
    Ugeskr Laeger; 1994 Feb; 156(6):832-3. PubMed ID: 8016994
    [No Abstract]   [Full Text] [Related]  

  • 12. [Scrutinizing information:"Negative publicity is the best sanction". The text of FASS (a drug index) is not an absolute norm].
    Finer D
    Lakartidningen; 1996 May; 93(21):2020-2, 2027-8. PubMed ID: 8649085
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacological information and the drug industry. The role of its medical departments].
    Castillo Pérez P
    Med Clin (Barc); 1987 Sep; 89(7):288-95. PubMed ID: 3316871
    [No Abstract]   [Full Text] [Related]  

  • 14. [What is happening with the institution for drug information scrutiny?].
    Håkansson J; Hensjö LO
    Lakartidningen; 1997 Jun; 94(24):2259-60. PubMed ID: 9213698
    [No Abstract]   [Full Text] [Related]  

  • 15. A standard of knowledge for pharmaceutical sales representatives.
    Bootman JL
    Manag Care Interface; 2006 Oct; 19(10):13. PubMed ID: 17117593
    [No Abstract]   [Full Text] [Related]  

  • 16. [Who will choose patients' medication in the future? Independent information must be strengthened II].
    Liedholm H; Linné AB; Ekedahl A
    Lakartidningen; 1996 Jun; 93(24):2315-7. PubMed ID: 8684030
    [No Abstract]   [Full Text] [Related]  

  • 17. Better communication urged for pharmaceutical manufacturers.
    Woods D
    Can Med Assoc J; 1984 Jun; 130(11):1488-9. PubMed ID: 6733620
    [No Abstract]   [Full Text] [Related]  

  • 18. Direct-to-consumer prescription drug advertising.
    Terzian TV
    Am J Law Med; 1999; 25(1):149-67. PubMed ID: 10207573
    [No Abstract]   [Full Text] [Related]  

  • 19. Secrecy and the health protection branch.
    Lexchin J
    CMAJ; 1998 Sep; 159(5):481-3. PubMed ID: 9757171
    [No Abstract]   [Full Text] [Related]  

  • 20. [Astra companies break the existing rules].
    Olsson B
    Lakartidningen; 1996 Apr; 93(15):1416. PubMed ID: 8667727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.